BRPI0108041B8 - nova forma galênica oral de liberação prolongada da molsidomina. - Google Patents
nova forma galênica oral de liberação prolongada da molsidomina.Info
- Publication number
- BRPI0108041B8 BRPI0108041B8 BRPI0108041A BR0108041A BRPI0108041B8 BR PI0108041 B8 BRPI0108041 B8 BR PI0108041B8 BR PI0108041 A BRPI0108041 A BR PI0108041A BR 0108041 A BR0108041 A BR 0108041A BR PI0108041 B8 BRPI0108041 B8 BR PI0108041B8
- Authority
- BR
- Brazil
- Prior art keywords
- molsidomine
- hours
- dosage form
- released
- angina
- Prior art date
Links
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 title abstract 11
- 229960004027 molsidomine Drugs 0.000 title abstract 11
- 239000002552 dosage form Substances 0.000 title abstract 3
- 238000013265 extended release Methods 0.000 title abstract 3
- 206010002383 Angina Pectoris Diseases 0.000 abstract 3
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 230000001148 spastic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
"nova forma galênica oral de liberação prolongada da molsidomina". a presente invenção se refere a uma nova forma galênica oral de liberação prolongada da molsidomina destinada ao tratamento da crise anginosa sob todas as suas formas (angina de esforço, angina espástica, angina mista). segundo a invenção, esta nova forma galênica contém uma quantidade terapeuticamente eficaz de molsidomina ou de um de seus metabólicos ativos e no que ela apresenta uma taxa de dissolução in vitro [medida espectrofotometricamente a 286 ou 311nm segundo o método descrito na pharmacopée européenne, 3<a> edição (ou u.s.p. xxiv) a 50 t.p.m em 500ml de um meio hc1 0,1 n, a 37 <198>c]de: - 15 a 25% de molsidomina liberada após 1 hora - 20 a 35% de molsidomina liberada após 2 horas - 50 a 65% de molsidomina liberada após 6 horas - 75 a 95% de molsidomina liberada após 12 horas - >85% de molsidomina liberada após 18 horas - >90% de molsidomina liberada após 24 horas o pico plasmático de molsidomina obtido in vivo se apresentando nas 2 horas e meia a 5 horas, de preferência nas 3 a 4 horas, seguindo a administração da citada forma e tendo um valor compreendido entre 25 e 40ng/ml de plasma. aplicação: indústria terapêutica
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0002307A FR2805462B1 (fr) | 2000-02-24 | 2000-02-24 | Nouvelle forme galenique orale a liberation prolongee de la molsidomine |
| PCT/EP2001/002055 WO2001062256A1 (fr) | 2000-02-24 | 2001-02-22 | Nouvelle forme galenique orale a liberation prolongee de la molsidomine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0108041A BR0108041A (pt) | 2002-10-29 |
| BR0108041B1 BR0108041B1 (pt) | 2013-06-18 |
| BRPI0108041B8 true BRPI0108041B8 (pt) | 2021-05-25 |
Family
ID=8847342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0108041A BRPI0108041B8 (pt) | 2000-02-24 | 2001-02-22 | nova forma galênica oral de liberação prolongada da molsidomina. |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US7767227B2 (pt) |
| EP (1) | EP1265614B1 (pt) |
| JP (1) | JP4945043B2 (pt) |
| KR (1) | KR100814191B1 (pt) |
| CN (1) | CN100396284C (pt) |
| AT (1) | ATE296632T1 (pt) |
| AU (2) | AU2001240653B9 (pt) |
| BE (1) | BE1013487A3 (pt) |
| BG (1) | BG66111B1 (pt) |
| BR (1) | BRPI0108041B8 (pt) |
| CA (1) | CA2400886C (pt) |
| CZ (1) | CZ301993B6 (pt) |
| DE (1) | DE60111196T2 (pt) |
| DZ (1) | DZ3273A1 (pt) |
| EE (1) | EE05098B1 (pt) |
| ES (1) | ES2241803T3 (pt) |
| FR (1) | FR2805462B1 (pt) |
| HK (1) | HK1050138B (pt) |
| HR (1) | HRP20020692B1 (pt) |
| HU (1) | HU229799B1 (pt) |
| IL (2) | IL151205A0 (pt) |
| IS (1) | IS2446B (pt) |
| MA (1) | MA25576A1 (pt) |
| MD (1) | MD3119C2 (pt) |
| MX (1) | MXPA02008262A (pt) |
| NO (1) | NO329495B1 (pt) |
| NZ (1) | NZ520691A (pt) |
| OA (1) | OA12183A (pt) |
| PL (1) | PL201631B1 (pt) |
| PT (1) | PT1265614E (pt) |
| RS (1) | RS50291B (pt) |
| RU (1) | RU2263506C2 (pt) |
| SK (1) | SK286313B6 (pt) |
| UA (1) | UA73972C2 (pt) |
| WO (1) | WO2001062256A1 (pt) |
| ZA (1) | ZA200206042B (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2805462B1 (fr) * | 2000-02-24 | 2003-08-15 | Therabel Res | Nouvelle forme galenique orale a liberation prolongee de la molsidomine |
| US7803402B2 (en) * | 2002-07-06 | 2010-09-28 | Sanjeev Khandelwal | Pharmaceutical preparations |
| FR2868314B1 (fr) * | 2004-04-05 | 2008-10-24 | Therabel Pharmaceuticals Ltd | Nouvelle utilisation therapeutique de la molsidomine et de ses sels pharmaceutiquement acceptables |
| EP2468269A1 (en) | 2010-11-26 | 2012-06-27 | Universitätsklinikum Münster | Nitric oxide donors in therapy of nitric oxide deficiency-induced disturbances of cerebral microcirculation |
| BE1028879B1 (fr) | 2020-12-11 | 2022-07-12 | Europharmaceuticals | Comprimé à libération prolongée de la molsidomine |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3522191A1 (de) * | 1985-06-21 | 1987-01-15 | Cassella Ag | Photostabilisierung von sydnoniminen |
| CN1006522B (zh) * | 1986-04-30 | 1990-01-24 | 田道制药有限公司 | 缓放性制剂的制备方法 |
| HU210921B (en) * | 1990-03-28 | 1995-09-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them |
| HU211648A9 (en) * | 1990-03-28 | 1995-12-28 | Chinoin Gyogyszer Es Vegyeszet | Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same |
| DE4140192C2 (de) * | 1991-12-05 | 1996-02-29 | Alfatec Pharma Gmbh | Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen |
| DE59408793D1 (de) * | 1993-05-11 | 1999-11-11 | Hoechst Ag | Galenische Zubereitungen von Molsidomin |
| WO1995001767A1 (en) * | 1993-07-08 | 1995-01-19 | Cygnus Therapeutic Systems | Monolithic matrix transdermal delivery system |
| IT1266565B1 (it) * | 1993-07-22 | 1997-01-09 | Ct Lab Farm Srl | Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico. |
| HU218280B (en) * | 1994-04-26 | 2000-07-28 | Cyclodextrin inclusion complexes containing sin-1a which are stable intheir solid state, process for their preparation and pharmaceutical compositions containing the comlexes | |
| DE4443105C2 (de) * | 1994-12-03 | 1997-03-13 | Hoechst Ag | Verfahren zur Herstellung Molsidomin-haltiger Tabletten |
| JPH09114680A (ja) * | 1995-10-19 | 1997-05-02 | Fuji Xerox Co Ltd | シーケンス制御装置 |
| IT1282576B1 (it) * | 1996-02-06 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili |
| PE57198A1 (es) * | 1996-03-25 | 1998-10-10 | American Home Prod | Formula de liberacion prolongada |
| JP2002522354A (ja) * | 1997-09-19 | 2002-07-23 | シャイア ラボラトリーズ，インコーポレイテッド | 固溶体ビードレット |
| FR2775188B1 (fr) * | 1998-02-23 | 2001-03-09 | Lipha | Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption |
| FR2805462B1 (fr) * | 2000-02-24 | 2003-08-15 | Therabel Res | Nouvelle forme galenique orale a liberation prolongee de la molsidomine |
-
2000
- 2000-02-24 FR FR0002307A patent/FR2805462B1/fr not_active Expired - Lifetime
-
2001
- 2001-02-22 JP JP2001561321A patent/JP4945043B2/ja not_active Expired - Lifetime
- 2001-02-22 DZ DZ013273A patent/DZ3273A1/fr active
- 2001-02-22 KR KR1020027010441A patent/KR100814191B1/ko active IP Right Grant
- 2001-02-22 CA CA2400886A patent/CA2400886C/fr not_active Expired - Lifetime
- 2001-02-22 EE EEP200200472A patent/EE05098B1/xx unknown
- 2001-02-22 CN CNB018052592A patent/CN100396284C/zh not_active Expired - Lifetime
- 2001-02-22 RS YUP-622/02A patent/RS50291B/sr unknown
- 2001-02-22 RU RU2002121503/15A patent/RU2263506C2/ru active
- 2001-02-22 AU AU2001240653A patent/AU2001240653B9/en not_active Expired
- 2001-02-22 PL PL357550A patent/PL201631B1/pl unknown
- 2001-02-22 MX MXPA02008262A patent/MXPA02008262A/es active IP Right Grant
- 2001-02-22 BE BE2001/0121A patent/BE1013487A3/fr not_active IP Right Cessation
- 2001-02-22 AU AU4065301A patent/AU4065301A/xx active Pending
- 2001-02-22 IL IL15120501A patent/IL151205A0/xx active IP Right Grant
- 2001-02-22 NZ NZ520691A patent/NZ520691A/en not_active IP Right Cessation
- 2001-02-22 AT AT01911692T patent/ATE296632T1/de active
- 2001-02-22 DE DE60111196T patent/DE60111196T2/de not_active Expired - Lifetime
- 2001-02-22 HU HU0300607A patent/HU229799B1/hu unknown
- 2001-02-22 EP EP01911692A patent/EP1265614B1/fr not_active Expired - Lifetime
- 2001-02-22 PT PT01911692T patent/PT1265614E/pt unknown
- 2001-02-22 CZ CZ20022876A patent/CZ301993B6/cs not_active IP Right Cessation
- 2001-02-22 ES ES01911692T patent/ES2241803T3/es not_active Expired - Lifetime
- 2001-02-22 WO PCT/EP2001/002055 patent/WO2001062256A1/fr active IP Right Grant
- 2001-02-22 BR BRPI0108041A patent/BRPI0108041B8/pt not_active IP Right Cessation
- 2001-02-22 SK SK1220-2002A patent/SK286313B6/sk not_active IP Right Cessation
- 2001-02-22 US US10/182,718 patent/US7767227B2/en not_active Expired - Fee Related
- 2001-02-22 MD MDA20020212A patent/MD3119C2/ro active IP Right Grant
- 2001-02-22 UA UA2002086983A patent/UA73972C2/uk unknown
- 2001-02-22 OA OA1200200258A patent/OA12183A/fr unknown
-
2002
- 2002-07-29 ZA ZA200206042A patent/ZA200206042B/xx unknown
- 2002-08-06 MA MA26765A patent/MA25576A1/fr unknown
- 2002-08-12 IL IL151205A patent/IL151205A/en unknown
- 2002-08-14 IS IS6504A patent/IS2446B/is unknown
- 2002-08-22 BG BG107027A patent/BG66111B1/bg unknown
- 2002-08-22 HR HR20020692A patent/HRP20020692B1/xx not_active IP Right Cessation
- 2002-08-23 NO NO20024043A patent/NO329495B1/no not_active IP Right Cessation
-
2003
- 2003-03-27 HK HK03102218.9A patent/HK1050138B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0312933A (pt) | Composição farmacêutica, unidade de dosagem farmacêutica, método para tratar uma ou mais doenças associadas com uma condição vascular, e, combinação terapêutica | |
| HUP0301868A2 (hu) | Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz | |
| BRPI0410503A (pt) | uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição | |
| DE60111539D1 (de) | Pharmazeutische zusammensetzung enthaltend ein 5-aminolaevulinsäure-ester als photochemotherapeutikum und ein mucoadhäsivum | |
| BR0109779A (pt) | Soluções moleculares hidrofìlicas dispersas de carvedilol | |
| ES2178430T3 (es) | Utilizacion de composiciones farmaceuticas gelificables en parodontologia. | |
| AR026610A1 (es) | Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central | |
| BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
| BR9810520A (pt) | Inibidor do fator xa isolado ou em combinação com um anti-agregador plaquetário, contra a trambose arterial | |
| AR040709A1 (es) | Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion | |
| BRPI0414500A (pt) | formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais | |
| HUP0203441A2 (hu) | L-karnitin és alkanoil-származékai alkalmazása ozmózisnyomás-szabályozó szerként és a gyógyászati alkalmazásra szánt oldatok | |
| BR0306928A (pt) | Composições farmacêuticas estáveis compreendendo inibidores de enzimas conversoras de angiotensina (ace) | |
| PT1425005E (pt) | Composicao farmaceutica que compreende lumiracoxib | |
| ATE451934T1 (de) | Pharmazeutische zusammensetzung zur behandlung von rhinitiden | |
| CO5570661A2 (es) | Combinaciones que comprenden inhibidores de cox-2 y aspirina | |
| BRPI0108041B8 (pt) | nova forma galênica oral de liberação prolongada da molsidomina. | |
| AR023687A1 (es) | Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa | |
| BR0206819A (pt) | Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca | |
| AR001765A1 (es) | Una formulación de liberación prolongada un procedimiento para su preparación una forma cristalina de cisaprida-(l)-tartrato y un medicamento util para el tratamiento de trastornos gastrointestinales | |
| AR036321A1 (es) | Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia. | |
| BRPI0410374A (pt) | composição farmacêutica que compreende valsartano | |
| AR039162A1 (es) | Formulaciones de venlafaxina de liberacion extendida | |
| Schep et al. | Primary interactions of three quaternary ammonium compounds with blastospores of Candida albicans (MEN strain) | |
| BR0214487A (pt) | Composição farmacêutica que compreende uma combinação de metformina e um ácido 4-oxobutanóico, e o uso da mesma para o tratamento de diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] |
Free format text: DE ACORDO COM O ART.34 "II" DA LPI (LEI 9279, DE 14/05/96), O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO. |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/06/2013, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/02/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 22/02/2021 |